Merck's Q3 2012 earnings call demonstrates strong performance despite the challenges of the Singulair patent expiration. Management highlighted growth in key products like JANUVIA/JANUMET, GARDASIL, and ZOSTAVAX, as well as robust expansion in emerging markets. Additionally, the advancement of their pipeline and continued cost management indicate a positive outlook.

[1]